Skip to main content
Top

Open Access 09-05-2024 | SARS-CoV-2 | COVID-19

Multiple sclerosis and COVID-19: a northern China survey

Authors: Qian Guo, Tianwei Wang, Yusen Huang, Fangruyue Wang, Pingping Hao, Le Fang

Published in: Neurological Sciences

Login to get access

Abstract

Background

There is insufficient data on severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) infection in Chinese patients with multiple sclerosis (pwMS). This study aims to explore the manifestation of pwMS during the Coronavirus disease 2019 (COVID-19) pandemic and the effect of SARS-CoV-2 infection on the prognosis of MS in northern China.

Methods

In this cross-sectional study, an online self-administered questionnaire and telephone interviews were conducted among pwMS of northern China. Clinical correlation of SARS-CoV-2 infection since the onset of the COVID-19 pandemic in northern China was analyzed.

Results

164 patients with an average age of 38.9 ± 12.2 years were included, of which 57.3% had a disease course ≤ 5 years. 33.5% of the patients were COVID-19 vaccinated. 87.2% received disease-modifying therapy (DMT), and the average immunotherapy duration was 1.9 ± 1.6 years. 83.5% were SARS-CoV-2 infected, 14.6% reported worsening of their original condition after infection, and 5.1% had a relapse of MS. Shorter disease course was independently related to infection risk (P = 0.046), whereas increasing age was related to aggravated behavioral symptoms (P = 0.008). However, gender, vaccination, and DMT were not associated with susceptibility or poor prognosis.

Conclusion

A shorter disease course is independently associated with an increased risk of SARS-CoV-2 infection, and age is associated with worsening disability. It seems to be safe and necessary to use DMT during the pandemic, however, the use of B cell-depletion agents should be approached with caution.
Literature
13.
go back to reference Beesley R, Cauchi M, Davies L, Upcott M, Norton E, Loveless S, Anderson V, Wynford-Thomas R, Pickersgill TP, Uzochukwu E, Wardle M, Robertson NP, Tallantyre E, Willis MD (2022) Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies. Mult Scler Relat Disord 68:104121. https://doi.org/10.1016/j.msard.2022.104121 Beesley R, Cauchi M, Davies L, Upcott M, Norton E, Loveless S, Anderson V, Wynford-Thomas R, Pickersgill TP, Uzochukwu E, Wardle M, Robertson NP, Tallantyre E, Willis MD (2022) Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies. Mult Scler Relat Disord 68:104121. https://​doi.​org/​10.​1016/​j.​msard.​2022.​104121
18.
19.
go back to reference Montini F, Nozzolillo A, Tedone N, Mistri D, Rancoita PM, Zanetta C, Mandelli A, Furlan R, Moiola L, Martinelli V, Rocca MA, Filippi M (2023) COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study. J Neurol Neurosurg Psychiatry jnnp-2023–332073. https://doi.org/10.1136/jnnp-2023-332073 Montini F, Nozzolillo A, Tedone N, Mistri D, Rancoita PM, Zanetta C, Mandelli A, Furlan R, Moiola L, Martinelli V, Rocca MA, Filippi M (2023) COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study. J Neurol Neurosurg Psychiatry jnnp-2023–332073. https://​doi.​org/​10.​1136/​jnnp-2023-332073
20.
go back to reference Angeletti S, Giovanetti M, Fogolari M, Cella E, De Florio L, Lintas C, Veralli R, Francesconi M, Caccuri F, De Cesaris M, De Flora C, Ceccarelli G, Spoto S, Caruso A, Pascarella S, Riva E, Ciccozzi M (2022) SARS‐CoV‐2 AY.4.2 variant circulating in Italy: genomic preliminary insight. J Med Virol 94(4):1689–92. https://doi.org/10.1002/jmv.27451 Angeletti S, Giovanetti M, Fogolari M, Cella E, De Florio L, Lintas C, Veralli R, Francesconi M, Caccuri F, De Cesaris M, De Flora C, Ceccarelli G, Spoto S, Caruso A, Pascarella S, Riva E, Ciccozzi M (2022) SARS‐CoV‐2 AY.4.2 variant circulating in Italy: genomic preliminary insight. J Med Virol 94(4):1689–92. https://​doi.​org/​10.​1002/​jmv.​27451
25.
go back to reference Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S (2021) Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 385(13):1172–83. https://doi.org/10.1056/NEJMoa2107659 Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S (2021) Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 385(13):1172–83. https://​doi.​org/​10.​1056/​NEJMoa2107659
26.
go back to reference Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU (2021) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 385(19):1761–1773. https://doi.org/10.1056/NEJMoa2110345CrossRefPubMed Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU (2021) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 385(19):1761–1773. https://​doi.​org/​10.​1056/​NEJMoa2110345CrossRefPubMed
27.
go back to reference Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U, Guber D, Stern Y, Polliack M, Falb R, Gurevich M (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler J 27(6):864–870. https://doi.org/10.1177/13524585211003476CrossRef Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U, Guber D, Stern Y, Polliack M, Falb R, Gurevich M (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler J 27(6):864–870. https://​doi.​org/​10.​1177/​1352458521100347​6CrossRef
28.
go back to reference Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza DA, Kadri JC, Markowitz DM, E. Markowitz C, Mexhitaj I, Jacobs D, Babb A, Betts MR, Prak ETL, Weiskopf D, Grifoni A, Lundgreen KA, Gouma S, Sette A, Bates P, Hensley SE, Greenplate AR, Wherry EJ, Li R, Bar-Or A (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27(11):1990–2001. https://doi.org/10.1038/s41591-021-01507-2 Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza DA, Kadri JC, Markowitz DM, E. Markowitz C, Mexhitaj I, Jacobs D, Babb A, Betts MR, Prak ETL, Weiskopf D, Grifoni A, Lundgreen KA, Gouma S, Sette A, Bates P, Hensley SE, Greenplate AR, Wherry EJ, Li R, Bar-Or A (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27(11):1990–2001. https://​doi.​org/​10.​1038/​s41591-021-01507-2
Metadata
Title
Multiple sclerosis and COVID-19: a northern China survey
Authors
Qian Guo
Tianwei Wang
Yusen Huang
Fangruyue Wang
Pingping Hao
Le Fang
Publication date
09-05-2024
Publisher
Springer International Publishing
Published in
Neurological Sciences
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-024-07578-6